649-P: The 7-Day Diabetes Education Hospitalization Program Improves Quality of Life and Treatment Satisfaction

Abstract

Essentials to achieving the goal of diabetes treatment are diabetes self-management education, medical nutrition therapy, and physical activity. In addition, patients with type 2 diabetes mellitus (T2DM) require a high level of treatment adherence, which is associated with treatment satisfaction and patients’ overall perception of quality of life (QoL). In our institute, we are routinely conducting a 7-day diabetes education hospitalization program using general strategy. For the patients participated in our program, we conducted diabetes treatment-related (DTR)-QoL questionnaire before admission and at discharge to evaluate treatment satisfaction and QoL with the effectiveness of our program. In this study, we investigated whether our program improves QoL and treatment satisfaction. In this retrospective study, we recruited the patients with T2DM who participated in a 7-day diabetes education hospitalization program in our institute from July 2017 to November 2019. We assessed the effect of our diabetes education hospitalization program on the QoL and treatment satisfaction by comparing the DTR-QoL scores before admission and at discharge. A total of 244 patients with T2DM were enrolled in this study. Patients’ baseline characteristics were (means ± SD) age: 60.3 ± 12.2 years, BMI: 26.4 ± 4.4 kg/m2, HbA1c: 8.6 ± 1.6%. During hospitalization, the number of types of glucose-lowering drugs per patient increased from 2.2 ± 1.4 to 2.9 ± 1.4 (P < 0.001). However, the DTR-QoL total score improved from 66.6 ± 13.0 to 69.5 ± 12.4 (P < 0.001). According to elements that constitute QoL, “Anxiety and dissatisfaction with treatment” score improved from 54.2 ± 19.8 to 59.2 ± 19.4 (P < 0.001) and “Satisfaction with treatment” score improved from 45.9 ± 18.6 to 59.3 ± 17.0 (P <0.001). In conclusion, our 7-day diabetes education hospitalization program could be and effective tool to improve QoL and treatment satisfaction and maintain high level of treatment adherence in patients with T2DM. Disclosure M. Kurita: None. H. Satoh: None. S. Kadowaki: None. H. Watada: Advisory Panel; Self; Abbott, Ajinomoto, Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Fuji Film, Janssen Pharmaceuticals, Inc., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation. Research Support; Self; Astellas Pharma Inc., Bayer Yakuhin, Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi-Aventis, Sanwa Kagaku Kenkyusho, Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Yakult. Speaker’s Bureau; Self; Astellas Pharma Inc., AstraZeneca, Bayer Yakuhin, Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Kowa Company, Ltd., Kyowa Hakko Kirin Co., Ltd., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi-Aventis, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited.